Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 358 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma March 25, 2022 AI is impacting cancer care, but also the environment September 25, 2025 Cancer in My Community: Advancements in Cancer Care in Singapore December 2, 2021 Study Examines Whether Blood Test Can Identify Early Cancers June 2, 2020 Load more HOT NEWS FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger... Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current...
